Personal profile
Research interests
My research is focused on pre-clinical studies and early phase clinical trials evaluating molecular therapeutic agents, including IGF-IR antibody and Chk1 inhibitors, for the treatment of breast cancer. Breast cancer cell lines and xenograft models as well as patients’ specimens are used to evaluate the mechanisms of action of these agents and to develop potential predictors of treatment response. A multi-center phase I/II study of IMC-A12 (ImClone Inc.), an IGF-IR antibody, in combination with temsirolimus in patients with metastatic breast cancer has been approved by NCI/CTEP to evaluate the efficacy and tolerability for the combined targeting of IGF-IR and mTOR. In collaboration with Drs. Helen Piwnica-Worms and Paula Fracasso, we are conducting an exploratory study of UCN-01, a Chk1 inhibitor, in combination with irinotecan in patients with triple negative breast cancer (negative for estrogen receptor, progesterone receptor and HER2 overexpression).
Clinical interests
Cancer, breast cancer
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial
Kong, T., Mabry, A., Highkin, M., Wang, A. Z., Hoog, J., Guo, Z., Gonzales-Gonzales, A., Thomas, S., Song, Y., Gao, F., Opyrchal, M., Peterson, L., Ademuyiwa, F., Margenthaler, J., Aft, R., Glover-Collins, K., Nehring, L., Tao, Y., Sanati, S. & Hagemann, I. S. & 14 others, , Dec 2026, In: Nature communications. 17, 1, 949.Research output: Contribution to journal › Article › peer-review
Open Access -
Imlunestrant, an oral selective estrogen receptor degrader, in combination with HER2 directed therapy, with or without abemaciclib, in ER-positive, HER2-positive advanced breast cancer: results from the phase 1a/1b EMBER study
Bhave, M., Jhaveri, K. L., Kaufman, P. A., Aftimos, P., Lombard, J., Giridhar, K. V., Im, S. A., Ma, C. X., Lee, K. T., Kim, S. B., Sohn, J., Li, Y., Yuen, E., Estrem, S. T., Nguyen, B., Makena, M. R., Ismail-Khan, R. & Beeram, M., Dec 2026, In: Breast Cancer Research. 28, 1, 18.Research output: Contribution to journal › Article › peer-review
Open Access1 Link opens in a new tab Scopus citations -
Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: expert opinion
Iyengar, N. M., O’Shaughnessy, J. A., Moore, H. N., Hamilton, E., Jhaveri, K. L., Ma, C. X., Tedesco, K., Vasekar, M., Donahue, S. & Rugo, H. S., Dec 2026, In: npj Breast Cancer. 12, 1, 16.Research output: Contribution to journal › Review article › peer-review
Open Access -
Unraveling TIME: CD8+ T cell- and CXCL11-driven endocrine resistance in breast cancer
Kong, T. & Ma, C. X., Feb 2 2026, In: The Journal of clinical investigation. 136, 3Research output: Contribution to journal › Article › peer-review
Open Access -
A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancer
Lloyd, M. R., Chica-Parrado, R., Weipert, C. M., Knepper, T. C., Podany, E. L., Napolitano, F., Ye, D., Lin, C. C., Uemoto, Y., Liao, J., Wegrzyn, C., Walko, C. M., Ryan, L. Y., Keenan, J. C., Medford, A. J., Liu, S. A., Wulf, G. M., Clifton, K. K., Ma, C. X. & Han, H. S. & 6 others, , Aug 2025, In: EBioMedicine. 118, 105828.Research output: Contribution to journal › Article › peer-review
Open Access5 Link opens in a new tab Scopus citations